Multiple Sclerosis Clinical Trial
Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis
This study is designed to determine whether symptom burden differs by time to infusion.
Diagnosis of multiple sclerosis (revised 2017 criteria)
Plans to initiate treatment with ocrelizumab within 6 months or has been on an approved regimen of ocrelizumab for >12 months as part of their clinical care
Individual must be able to provide consent, read/write/comprehend English Language
Clinical relapse within 3 months of first on-study infusion
Cognitive impairment limiting the ability to consent or fill out the electronic survey
Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding
Untreated psychiatric illness (such as major depressive disorder, Bipolar disorder, psychotic disorder, schizophrenia)
Active substance abuse disorder
Significant medical comorbidities (such as history of severe traumatic brain injury, stroke, systemic cancer or chronic infection)
Chemotherapy use within 6 months of first study infusion
Prior treatment with alemtuzumab within 12 months of first study infusion
Prior treatment with a B-cell depleting therapy other than ocrelizumab within 12 months of first on-study infusion
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Wellesley Massachusetts, 02481, United States
New York New York, 10016, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.